Malta - English - Medicines Authority

merck sharp & dohme b.v. waarderweg 39, haarlem noord-holland, 2031 bn, netherlands - varicella virus, oka, merck strain, live, attenuated - powder and solvent for suspension for injection - varicella virus oka/merck strain (live, attenuated) - vaccines

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - water for injections, quantity: 0.85 ml - diluent, not applicable - excipient ingredients: - this product approved for registration as an amendment to a product accepted for inclusion in the artg as 'currently supplied' at the commencement of the therapeutic goods act 1989. indications are held in artg paper records. (old code)

Israel - English - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - measles virus enders edmonston strain (live, attenuated); mumps virus jeryl lynn™ (level b) strain (live, attenuated); rubella virus wistar ra 27/3 strain (live, attenuated); varicella virus oka/merck strain (live, attenuated) - powder and solvent for suspension for injection - measles virus enders edmonston strain (live, attenuated); varicella virus oka/merck strain (live, attenuated); rubella virus wistar ra 27/3 strain (live, attenuated); mumps virus jeryl lynn™ (level b) strain (live, attenuated) - measles, combinations with mumps, rubella and varicella, live attenuated - proquad is indicated for simultaneous vaccination against measles, mumps, rubella, and varicella in individuals from 12 months of age to 12 years of age.proquad can be administered to individuals from 9 months of age under special circumstances: outbreak situations, or travel to a region with high prevalence of measles.

Israel - English - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - raltegravir as potassium - film coated tablets - raltegravir as potassium 400 mg - raltegravir - raltegravir - isentress is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infection in adult patients.this indication is based on safety and efficacy data from two double-blind, placebo-controlled trials in treatment-experienced patients and one double-blind, active-controlled trial in treatment-naive patients.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck sharp & dohme (uk) ltd - varicella-zoster virus live attenuated (oka/merck strain) - powder and solvent for suspension for injection

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck sharp & dohme ltd - varicella-zoster virus live attenuated (oka/merck strain) - powder and solvent for suspension for injection

United States - English - NLM (National Library of Medicine)

merck sharp & dohme llc - varicella-zoster virus strain oka/merck live antigen (unii: gpv39zgd8c) (varicella-zoster virus strain oka/merck live antigen - unii:gpv39zgd8c) - varicella-zoster virus strain oka/merck live antigen 19400 [pfu] in 0.65 ml - zostavax® is a live attenuated virus vaccine indicated for prevention of herpes zoster (shingles) in individuals 50 years of age and older. limitations of use of zostavax: - zostavax is not indicated for the treatment of zoster or postherpetic neuralgia (phn). - zostavax is not indicated for prevention of primary varicella infection (chickenpox). do not administer zostavax to individuals with a history of anaphylactic/anaphylactoid reaction to gelatin, neomycin or any other component of the vaccine. neomycin allergy manifested as contact dermatitis is not a contraindication to receiving this vaccine. {1} do not administer zostavax to individuals who are immunodeficient or immunosuppressed due to disease or therapy, as serious or fatal disseminated vaccine strain varicella-zoster virus disease may occur. causes of immunodeficiency or immunosuppression may include, but are not limited to, primary or acquired immunodeficiency states, aids or other clinical manifestations of infection with human immunodeficiency

European Union - English - EMA (European Medicines Agency)

merck sharp dohme ltd - laropiprant, nicotinic acid - dyslipidemias - lipid modifying agents - pelzont is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (ldl) cholesterol and triglycerides and low high-density-lipoprotein (hdl)cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).pelzont should be used in patients in combination with 3-hydroxy-3-methylglutaryl-coenzyme-a (hmg-coa)-reductase inhibitors (statins), when the cholesterol lowering effect of hmg-coa-reductase inhibitor monotherapy is inadequate. it can be used as monotherapy only in patients in whom hmg-coa-reductase inhibitors are considered inappropriate or not tolerated. diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with pelzont.

European Union - English - EMA (European Medicines Agency)

merck sharp dohme ltd. - laropiprant, nicotinic acid - dyslipidemias - lipid modifying agents - tredaptive is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (ldl) cholesterol and triglycerides and low high-density-lipoprotein (hdl) cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).tredaptive should be used in patients in combination with 3-hydroxy-3-methyl-glutaryl-co-enzyme-a (hmg-coa)-reductase inhibitors (statins), when the cholesterol-lowering effect of hmg-coa-reductase inhibitor monotherapy is inadequate. it can be used as monotherapy only in patients in whom hmg-coa-reductase inhibitors are considered inappropriate or not tolerated. diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with tredaptive.

European Union - English - EMA (European Medicines Agency)

merck sharp dohme ltd - laropiprant, nicotinic acid - dyslipidemias - lipid modifying agents - trevaclyn is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (ldl) cholesterol and triglycerides and low high-density-lipoprotein (hdl) cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).trevaclyn should be used in patients in combination with 3-hydroxy-3-methyl-glutaryl-co-enzyme-a (hmg-coa)-reductase inhibitors (statins), when the cholesterol-lowering effect of hmg-coa-reductase-inhibitor monotherapy is inadequate. it can be used as monotherapy only in patients in whom hmg-coa-reductase inhibitors are considered inappropriate or not tolerated. diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with trevaclyn.